In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

EHRA endorsed documents

Publications endorsed by the European Heart Rhythm Association (EHRA)

Atrial Fibrillation

 

Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting With Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention / Stenting

A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rythym Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]
Gregory Y.H.Lip, Kurt Huber, Felicita Andreotti, Harald Arnesen, K. Juhani Airaksinen, Thomas Cuisset, Paulus Kirchhof, Francisco Marin
Thromb Haemost 2009; 102

Summary: there remains uncertainty over optimal antithrombotic management strategy for patients with atrial fibrillation (AF) presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Clinicians need to balance the risk of stroke and thromboembolism against the risk of recurrent cardiac ischaemia and/or stent thrombosis, and the risk of bleeding. This consensus document comprehensively reviews the published evidence and presents a consensus statement on a "best practice" antithrombotic therapy guideline for the management of antithrombotic therapy such as AF patients. Gregory Y.H.Lip, Kurt Huber, Felicita Andreotti, Harald Arnesen, K. Juhani Airaksinen, Thomas Cuisset, Paulus Kirchhof, Francisco Marinthere remains uncertainty over optimal antithrombotic management strategy for patients with atrial fibrillation (AF) presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Clinicians need to balance the risk of stroke and thromboembolism against the risk of recurrent cardiac ischaemia and/or stent thrombosis, and the risk of bleeding. This consensus document comprehensively reviews the published evidence and presents a consensus statement on a "best practice" antithrombotic therapy guideline for the management of antithrombotic therapy such as AF patients.

Read the full text